Prothena Corporation Plc (PRTA) 19.81 $PRTA
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 100.36 (+1.16), PTLA: 26.88 (-0.33), PFE: 28.28 (+0.35), BMY: 51.95 (+1.39), PRTA: 19.81 (-0.33), PBYI: 228.08 (+2.55)
Why Prothena Corporation (PRTA) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 7:43AM CDT
Prothena Corporation belongs to the Medical and Biomedical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
PRTA: 19.81 (-0.33)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
KMX: 48.80 (+1.72), CRUS: 21.16 (+0.13), MEI: 36.41 (+0.97), PRTA: 19.81 (-0.33), GPX: 29.14 (+0.07)
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
GlobeNewswire - Tue Aug 26, 3:08PM CDT
-- Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's Disease
PRTA: 19.81 (-0.33)
Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
Thomson Reuters ONE - Mon Aug 18, 3:05PM CDT
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the 2014 Rejuvenation Biotechnology Conference, a SENS Research Foundation Conference, on Friday, August 22, 2014.
PRTA: 19.81 (-0.33)
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress
GlobeNewswire - Mon Aug 04, 3:06PM CDT
-- Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quarter 2014 contributed to strengthen cash position to $303.9 million
PRTA: 19.81 (-0.33)
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
GlobeNewswire - Thu Jul 31, 3:12PM CDT
-- First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
PRTA: 19.81 (-0.33)
Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...
BMY: 51.95 (+1.39), PRTA: 19.81 (-0.33), FPRX: 12.20 (+0.12)
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
DUBLIN, Ireland , June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares.
PRTA: 19.81 (-0.33)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
BIIB: 326.77 (+15.36), ONCY: 0.47 (-0.06), ANIP: 28.09 (+0.30), PRTA: 19.81 (-0.33)
Prothena to launch public offering of USD100m ordinary shares
M2 - Tue Jun 24, 4:22AM CDT
Biotechnology company Prothena Corporation plc (NasdaqGS RTA) said on Monday that it plans to begin a public offering of USD100m of its ordinary shares.
PRTA: 19.81 (-0.33)
Prothena Announces Proposed Offering of Ordinary Shares
Thomson Reuters ONE - Mon Jun 23, 3:20PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 19.81 (-0.33)
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
PRGO: 150.16 (+1.69), ACT: 232.13 (+5.46), ICPT: 225.71 (-5.62), PRTA: 19.81 (-0.33), FRX: 99.00 (-0.77)
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
KYTH: 33.29 (+0.94), PFE: 28.28 (+0.35), ALR: 37.98 (+0.67), PRTA: 19.81 (-0.33), MGLN: 58.08 (+1.39)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 100.36 (+1.16), PTLA: 26.88 (-0.33), PFE: 28.28 (+0.35), BMY: 51.95 (+1.39), PRTA: 19.81 (-0.33), PBYI: 228.08 (+2.55)
Why Prothena Corporation (PRTA) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 7:43AM CDT
Prothena Corporation belongs to the Medical and Biomedical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
PRTA: 19.81 (-0.33)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
KMX: 48.80 (+1.72), CRUS: 21.16 (+0.13), MEI: 36.41 (+0.97), PRTA: 19.81 (-0.33), GPX: 29.14 (+0.07)
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
GlobeNewswire - Tue Aug 26, 3:08PM CDT
-- Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's Disease
PRTA: 19.81 (-0.33)
Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
Thomson Reuters ONE - Mon Aug 18, 3:05PM CDT
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the 2014 Rejuvenation Biotechnology Conference, a SENS Research Foundation Conference, on Friday, August 22, 2014. PRTA: 19.81 (-0.33)
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress
GlobeNewswire - Mon Aug 04, 3:06PM CDT
-- Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quarter 2014 contributed to strengthen cash position to $303.9 million
PRTA: 19.81 (-0.33)
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
GlobeNewswire - Thu Jul 31, 3:12PM CDT
-- First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
PRTA: 19.81 (-0.33)
Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...
BMY: 51.95 (+1.39), PRTA: 19.81 (-0.33), FPRX: 12.20 (+0.12)
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
Thomson Reuters ONE - Thu Jun 26, 9:45PM CDT
DUBLIN, Ireland , June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares. PRTA: 19.81 (-0.33)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
BIIB: 326.77 (+15.36), ONCY: 0.47 (-0.06), ANIP: 28.09 (+0.30), PRTA: 19.81 (-0.33)
Prothena to launch public offering of USD100m ordinary shares
M2 - Tue Jun 24, 4:22AM CDT
Biotechnology company Prothena Corporation plc (NasdaqGS
RTA) said on Monday that it plans to begin a public offering of USD100m of its ordinary shares. PRTA: 19.81 (-0.33)
Prothena Announces Proposed Offering of Ordinary Shares
Thomson Reuters ONE - Mon Jun 23, 3:20PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 19.81 (-0.33)
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
PRGO: 150.16 (+1.69), ACT: 232.13 (+5.46), ICPT: 225.71 (-5.62), PRTA: 19.81 (-0.33), FRX: 99.00 (-0.77)
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
KYTH: 33.29 (+0.94), PFE: 28.28 (+0.35), ALR: 37.98 (+0.67), PRTA: 19.81 (-0.33), MGLN: 58.08 (+1.39)
